

.____

In the UK, 9 out of 10 overdose deaths (89%) involved some form of opioid¹


Take-home naloxone (THN)

Individuals leaving prisons are particularly vulnerable to opioid overdose within the immediate post-release period²

~3-8-fold increased risk of drug-related deaths

in the first 2 weeks after release in comparison to the subsequent 10 weeks³





What can you do to prevent these deaths?

Currently, in England...

Only a third of adults leaving prison engaged with their community drug treatment provider within 21 days of release⁵



Liberation Day

What is naloxone?⁷

A **life-saving medicine** that can reverse potentially fatal breathing impairment caused by opioid overdose

Supplied by drug treatment services commissioned by local authorities or the NHS for use in an emergency⁸

Available as an intranasal spray or pre-filled syringe

No abuse potential, and adverse reactions are extremely rare

Case study:

THN training

Between 2011-16, Scotland's national naloxone programme (NNP) distributed ~36,000 (~5,000 in prisons) THN kits. During this time, opioid-related deaths within 4 weeks of prison release declined by 50%.⁶



Take-home naloxone (THN)



THN programmes in prisons

of prisons and custodial establishments in England had no THN programme in 2017/18.²



In the prison setting, naloxone training can be provided to prisoners:

- Just before release
- In a group session(s)
- As 1:1 peer-led or staff-led training sessions
- In the individual's induction to the prison when they arrive

Training can also be offered to untrained members of staff, visiting family members and friends

THN should be given to anyone who:

- Requests THN
- Is at risk of overdose
- Is likely to witness an overdose (e.g. family)



Step 1

Training generally includes:

of detained people who inject drugs

say they would use THN to

resuscitate a friend if they

were trained⁹

- Identifying signs of an overdose
- When to call the ambulance
- When to provide naloxone
- The recovery position and CPR
- How to use the THN kit

How can THN be implemented in the prison setting?



Contact your healthcare service provider, NHS England, drug services, prison governors, local commissioner or MP to secure funding for a THN programme








For more information on THN programmes, visit:

- EuroNPUD. Naloxone access and advocacy project (UK), 2019: https://static1.squarespace.com/ static/58321 efcd 1758e26bb49208d/t/5cc 1981 b71 c10b09dab48ac4/1556191397550/EuroNPUD_Naloxone_Access_and_ Advocacy_Project_Process_Report_final.pdf
- EuroNPUD. Peer-to-peer distribution of naloxone (P2PN) technical briefing, 2019: https://static1.squarespace.com/ static/58321efcd1758e26bb49208d/t/5cc1b6e58165f5f7caf78294/1556199312966/EuroNPUD_Technical_Briefing_P2P_ Naloxone_final_3.pdf
- EMCDDA. Preventing opioid overdose deaths with take-home naloxone, 2016: http://www.emcdda.europa.eu/system/files/ publications/2089/TDXD15020ENN.pdf
- Public Health Wales. Harm Reduction Database Wales-Take Home Naloxone, 2017:18: http://www.wales.nhs.uk/sitesplus/ documents/888/Naloxone%20HRD%20report%202017-18.pdf
- NHS Scotland. National Naloxone Programme Scotland, 2017/18 Monitoring report: https://www.isdscotland.org/Health-Topics/Drugs-and-Alcohol-Misuse/Publications/2018-11-27/2018-11-27-Naloxone-Report.pdf
- SDF Scottish Drugs Forum: www.sdftraining.org.uk
- Public Health England: https://www.gov.uk/government/publications/providing-take-home-naloxone-for-opioid-overdose
- Harm Reduction Coalition: https://harmreduction.org/issues/overdose-prevention/overview/overdose-basics/understandingnaloxone/ (US): https://harmreduction.org/wp-content/uploads/2012/11/od-manual-final-links.pdf
- IDPC: Naloxone-on-Release: http://fileserver.idpc.net/library/My_first_48_hours_out_Naloxone-on-Release_Guidelines1.pdf
- Guidance on regulations 'widening the availability of naloxone': https://www.gov.uk/government/publications/widening-the-availability-of-naloxone/widening-the-availability-of-naloxone
- IOTOD THN toolkit: https://iotodeducation.com/resources-and-tools/case-studies/

References:

EMCDDA. European Drug Report, 2019; 2. Release. Finding a needle in haystack - 2017/2018, 2019; 3. Merral et al. Addiction 2010; 105(9):1545-1554;
Strang et al. J Urban Health 2013; 90(5):983-996; 5. Public Health England. Secure setting substance misuse statistics from NDTMS, 2019; 6. Bird SM, McAuley A. Scotland's National Naloxone Programme. Lancet 2019; 393:10169. 7.EMCDDA. Preventing opioid overdose deaths with THN, 2016; 8. Peter Burkinshaw. PHE Naloxone in England: national policy for local action, 2017: https://www.addiction-ssa.org/images/uploads/PETE_BURKINSHAW_Naloxone_for_NAC_100317. pdf 9. Curtis et al. Harm Reduction Journal 2018;15:48; 10. EMC, 2018: https://www.medicines.org.uk/emc/product/3590/smpc/; 11. EMC, 2019: https://www.medicines.org.uk/emc/product/9292; 12. NHS, 2019: https://www.lambethccg.nhs.uk/news-and-publications/meeting-papers/south-east-london-area-prescribing-committee/Documents/New%20Medicine%20Recommendations/Recommendation%20102%20Naloxone%20nasal%20Nyxoid%20(RED)%20



The take-home naloxone (THN) resource kit programme is supported by funding from Ethypharm UK Ltd. All educational content and materials are created by Educational Advisors in collaboration with PCM Scientific, the medical education company acting as secretariat. Ethypharm UK Ltd has had no involvement in the creation or development of the educational content.

